Mechanism

How it works

HGH binds to the GH receptor (GHR), a class I cytokine receptor, triggering JAK2-STAT5 signaling pathways that stimulate transcription of insulin-like growth factor 1 (IGF-1) primarily in the liver. IGF-1 then mediates most of the anabolic effects of GH — including protein synthesis, cellular proliferation, and longitudinal bone growth — while GH itself directly promotes lipolysis in adipose tissue via hormone-sensitive lipase activation. GH also antagonizes insulin signaling, increasing hepatic glucose output and promoting free fatty acid mobilization.

Reported in research

Benefits

Significant increases in lean muscle mass and protein synthesis via IGF-1 upregulation
Enhanced lipolysis and reduction in visceral and subcutaneous adipose tissue
Accelerated recovery from injury, improved tissue repair, and enhanced collagen synthesis
Improved sleep quality, bone mineral density, and overall body composition in GH-deficient individuals
Potential anti-aging effects including improved skin elasticity, energy levels, and organ health

Context, not a prescription

Dosing

Typical range: 1–4 IU/day for anti-aging/fat loss; up to 6–8 IU/day for bodybuilding (clinical replacement: 0.2–0.4 IU/day) (Subcutaneous, Intramuscular)
Cycle length: 12–24 weeks minimum for notable body composition changes; clinical protocols are indefinite
Half-life: ~15–20 minutes (endogenous GH pulse); ~3–5 hours (exogenous rhGH subcutaneous)

Safety

Side effects & contraindications

Possible side effects

Fluid retention and edema, particularly in extremities
Carpal tunnel syndrome due to nerve compression from fluid accumulation
Insulin resistance and elevated fasting blood glucose
Joint and muscle pain (arthralgias, myalgias)
Acromegaly-like features with long-term supraphysiological use (enlarged hands, feet, jaw)
Elevated IGF-1 potentially linked to cancer cell proliferation with chronic overuse
Hypothyroidism due to increased T4-to-T3 conversion demands
Injection site reactions including lipohypertrophy or lipoatrophy

Contraindications

Active malignancy or history of cancer (GH stimulates IGF-1 which may promote tumor growth)
Diabetic retinopathy or poorly controlled diabetes mellitus
Acute critical illness (post-surgery, trauma, respiratory failure)
Closed epiphyseal plates if used for height enhancement in minors without medical supervision
Prader-Willi syndrome patients with severe obesity or respiratory impairment
Pregnancy and breastfeeding without physician guidance

Research information, not medical advice. Always consult a licensed clinician before considering any peptide.

In depth

Full profile

What it does

Over time, users typically notice improved sleep quality, reduced body fat (especially around the midsection), firmer skin, improved muscle tone and recovery between workouts, and increased energy levels. Bone density improvements take many months to show up.

How it works

Think of HGH as a construction company dispatcher — when the dispatcher (HGH) sends out more work orders, construction crews (IGF-1 and other signals) get busy building new muscle, repairing old tissue, and clearing out fat storage like demolishing old buildings to make room for new ones.

After injection, HGH is absorbed into the bloodstream and travels to receptors on cells throughout the body — especially in the liver, muscle, and fat tissue. The liver then produces IGF-1, which drives protein synthesis and cell growth. At the same time, HGH directly tells fat cells to break down and release stored energy.

What to expect

Initial effects like better sleep and improved energy may be noticed within 1–2 weeks. Visible changes in body composition typically begin after 4–6 weeks and become more pronounced after 3–6 months of consistent use.

Weeks 1–2: Better sleep quality, slightly more vivid dreams, mild increase in energy. Some users notice early water retention or hand tingling.
Weeks 2–6: Improved workout recovery, subtle reduction in body fat, noticeable improvement in skin texture and hydration. Water retention may peak then stabilize.
Weeks 6–24+: Significant lean muscle gains, meaningful fat loss (especially visceral fat), improved joint comfort, and enhanced overall body composition. Full effects require long-term consistent use.

Good to know

Start at a low dose (1–2 IU/day) and increase slowly to assess tolerance
Inject in the evening or before bed to mimic natural GH pulses and improve sleep quality
Monitor fasting blood glucose and IGF-1 levels every 6–8 weeks
Stay well hydrated to manage water retention side effects
Work with a physician who can order regular bloodwork and adjust dosing

Staying safe

Water retention causing puffy hands, feet, or face — especially early on
Tingling or numbness in the hands (carpal tunnel-like symptoms)
Mild joint aches or stiffness
Elevated blood sugar levels — more noticeable if taken with meals

Avoid if you have:

Anyone with a history of cancer or active tumors
People with uncontrolled diabetes
Pregnant or breastfeeding women
Anyone under 18 without a physician-diagnosed growth disorder

Overview

Sustained rhGH administration at supraphysiological doses produces: increased lean body mass (mean +3–5 kg over 6 months in GH-deficient adults in RCTs), decreased fat mass (mean −3–4 kg), improved VO2 max, enhanced collagen type I and III synthesis, increased bone mineral density (primarily after 12+ months), and IGF-1 normalization or elevation above normal range. Carbohydrate metabolism is impaired — fasting insulin levels rise and insulin sensitivity (measured by HOMA-IR) decreases by 20–35% in dose-dependent fashion.

How it works

GH receptor dimerization functions like two-key authentication on a safe — only when both receptor subunits are occupied and locked together does the JAK2 kinase 'turn on' and open the transcriptional programs downstream. IGF-1 then acts as a distributed secondary messenger — essentially a hormonal proxy that carries specific construction blueprints (anabolic signals) to muscle, bone, and connective tissue throughout the body.

Following subcutaneous injection, rhGH is absorbed with a bioavailability of approximately 75–80%, reaching peak serum concentrations (Cmax) within 2–4 hours. It is cleared primarily through hepatic and renal metabolism with a plasma half-life of 3–5 hours. IGF-1 levels rise with a delay of 8–24 hours post-injection and remain elevated for 12–18 hours, providing the sustained anabolic window. Chronic administration upregulates hepatic GHR density and increases basal IGF-1 substantially — clinical studies show IGF-1 increases of 30–60% from baseline at doses of 2–4 IU/day. GH also stimulates thyroid hormone metabolism, increasing T4-to-T3 conversion demands through deiodinase activity, potentially precipitating subclinical hypothyroidism.

Onset & timeline

JAK2-STAT5 pathway activation occurs within minutes of receptor binding. Serum IGF-1 elevation is detectable within 8–12 hours post-injection. Measurable changes in nitrogen balance and lipolysis markers appear within 3–7 days of initiation. Detectable changes in lean body mass via DEXA scan typically emerge after 4–8 weeks at therapeutic doses (2–4 IU/day).

Days 1–7: JAK2-STAT5 signaling activates within hours of first injection. Serum IGF-1 rises measurably by day 2–3. Early fluid retention from renal sodium reabsorption may cause transient weight gain of 1–3 lbs. GH-mediated lipolysis begins, with elevated plasma free fatty acids detectable within 24–48 hours.
Weeks 1–4: Sustained IGF-1 elevation drives positive nitrogen balance and early anabolic remodeling. Sleep architecture improves (increased slow-wave/stage 3 sleep). Lipolytic effects become systemic — visceral adipocytes are particularly sensitive to GH-mediated HSL activation. Carpal tunnel symptoms may emerge in sensitive individuals as interstitial fluid accumulates.
Weeks 4–24+: Progressive lean mass accretion (predominantly myofibrillar protein synthesis augmented by IGF-1/IGF-1R signaling) becomes measurable by DEXA. Visceral and subcutaneous fat decreases measurably. Collagen synthesis improvements manifest as improved skin elasticity and tendon/ligament resilience. Bone turnover markers (osteocalcin, P1NP) rise, reflecting increased osteoblast activity. At 6 months, full metabolic reprogramming toward anabolic/lipolytic phenotype is established.

Getting the most from it

Monitor serum IGF-1 every 6–8 weeks; keep IGF-1 within age-adjusted normal range (typically 150–300 ng/mL for adults) to minimize neoplastic risk
Regular fasting glucose and HbA1c monitoring; consider berberine or metformin co-administration if insulin resistance develops
Thyroid panel (TSH, free T3, free T4) every 3–4 months; supplement T3 or T4 if subclinical hypothyroidism emerges
Use pulsatile injection timing (single daily dose before sleep or split 5-days-on/2-days-off protocol) to maintain pituitary sensitivity and reduce tachyphylaxis
Split dosing (e.g., morning + evening injections) at higher dose ranges to reduce peak IGF-1 spikes and moderate insulin antagonism
Annual MRI or relevant imaging in individuals with prior benign tumors or pituitary adenoma history

Common side effects

Peripheral edema due to sodium and water retention from GH-mediated renal tubular sodium reabsorption — affects 10–20% of users at clinical doses
Carpal tunnel syndrome from fluid accumulation compressing the median nerve — incidence approximately 10–15% at doses >2 IU/day
Insulin resistance and hyperinsulinemia — clinically significant at doses >3–4 IU/day, particularly in those with pre-existing metabolic syndrome
Arthralgias and myalgias — transient in most users, resolving with dose reduction

Mechanism of action

Recombinant human growth hormone (rhGH) binds as a bivalent ligand to two GH receptor (GHR) molecules, inducing receptor homodimerization and transactivation of the associated Janus kinase 2 (JAK2). JAK2 phosphorylates the intracellular domain of GHR and recruits STAT5b (signal transducer and activator of transcription 5b), which dimerizes and translocates to the nucleus to drive transcription of IGF-1, IGF-binding proteins, and other anabolic gene targets. In parallel, GH activates the MAPK/ERK and PI3K/AKT signaling cascades in peripheral tissues — promoting lipolysis in adipocytes through phosphorylation of hormone-sensitive lipase and perilipin, and inducing a counter-regulatory anti-insulin effect via IRS-1 serine phosphorylation that reduces GLUT4 translocation.

Following subcutaneous injection, rhGH is absorbed with a bioavailability of approximately 75–80%, reaching peak serum concentrations (Cmax) within 2–4 hours. It is cleared primarily through hepatic and renal metabolism with a plasma half-life of 3–5 hours. IGF-1 levels rise with a delay of 8–24 hours post-injection and remain elevated for 12–18 hours, providing the sustained anabolic window. Chronic administration upregulates hepatic GHR density and increases basal IGF-1 substantially — clinical studies show IGF-1 increases of 30–60% from baseline at doses of 2–4 IU/day. GH also stimulates thyroid hormone metabolism, increasing T4-to-T3 conversion demands through deiodinase activity, potentially precipitating subclinical hypothyroidism.

Pharmacodynamics

JAK2-STAT5 pathway activation occurs within minutes of receptor binding. Serum IGF-1 elevation is detectable within 8–12 hours post-injection. Measurable changes in nitrogen balance and lipolysis markers appear within 3–7 days of initiation. Detectable changes in lean body mass via DEXA scan typically emerge after 4–8 weeks at therapeutic doses (2–4 IU/day).

Sustained rhGH administration at supraphysiological doses produces: increased lean body mass (mean +3–5 kg over 6 months in GH-deficient adults in RCTs), decreased fat mass (mean −3–4 kg), improved VO2 max, enhanced collagen type I and III synthesis, increased bone mineral density (primarily after 12+ months), and IGF-1 normalization or elevation above normal range. Carbohydrate metabolism is impaired — fasting insulin levels rise and insulin sensitivity (measured by HOMA-IR) decreases by 20–35% in dose-dependent fashion.

Timeline

Days 1–7: JAK2-STAT5 signaling activates within hours of first injection. Serum IGF-1 rises measurably by day 2–3. Early fluid retention from renal sodium reabsorption may cause transient weight gain of 1–3 lbs. GH-mediated lipolysis begins, with elevated plasma free fatty acids detectable within 24–48 hours.
Weeks 1–4: Sustained IGF-1 elevation drives positive nitrogen balance and early anabolic remodeling. Sleep architecture improves (increased slow-wave/stage 3 sleep). Lipolytic effects become systemic — visceral adipocytes are particularly sensitive to GH-mediated HSL activation. Carpal tunnel symptoms may emerge in sensitive individuals as interstitial fluid accumulates.
Weeks 4–24+: Progressive lean mass accretion (predominantly myofibrillar protein synthesis augmented by IGF-1/IGF-1R signaling) becomes measurable by DEXA. Visceral and subcutaneous fat decreases measurably. Collagen synthesis improvements manifest as improved skin elasticity and tendon/ligament resilience. Bone turnover markers (osteocalcin, P1NP) rise, reflecting increased osteoblast activity. At 6 months, full metabolic reprogramming toward anabolic/lipolytic phenotype is established.

Comparisons

HGH (rhGH) — effectiveness Very High, safety Moderate, cost $$$$, High to use
Ipamorelin + CJC-1295 — effectiveness High, safety Good, cost $$, Medium to use
IGF-1 LR3 — effectiveness High, safety Caution, cost $$$, High to use
Sermorelin — effectiveness Moderate, safety Good, cost $$, Medium to use

Adverse effects

Common:

Peripheral edema due to sodium and water retention from GH-mediated renal tubular sodium reabsorption — affects 10–20% of users at clinical doses
Carpal tunnel syndrome from fluid accumulation compressing the median nerve — incidence approximately 10–15% at doses >2 IU/day
Insulin resistance and hyperinsulinemia — clinically significant at doses >3–4 IU/day, particularly in those with pre-existing metabolic syndrome
Arthralgias and myalgias — transient in most users, resolving with dose reduction

Rare:

Intracranial hypertension (pseudotumor cerebri) — rare, primarily in pediatric populations (<1%)
Pancreatitis — rare case reports, mechanism unclear but possibly related to lipid metabolism changes
New-onset type 2 diabetes mellitus with prolonged supraphysiological use — estimated incidence 1–2% in long-term studies
Progression of pre-existing neoplasms — theoretical risk supported by IGF-1's mitogenic role; no definitive causal RCT data in adults

Contraindications & risk mitigation

Contraindicated in:

Patients with active or suspected malignancy — GH/IGF-1 axis promotes cell proliferation via PI3K/AKT and MAPK pathways
Individuals with diabetic retinopathy — retinal neovascularization may be exacerbated by IGF-1-mediated VEGF upregulation
Patients with severe obesity (BMI >40) — increased risk of adverse metabolic effects including worsened insulin resistance
Individuals with untreated hypothyroidism — GH increases peripheral T4-to-T3 conversion, potentially unmasking subclinical deficiency
Those with active Prader-Willi syndrome and compromised respiratory function — increased risk of sleep apnea and sudden death

Monitor serum IGF-1 every 6–8 weeks; keep IGF-1 within age-adjusted normal range (typically 150–300 ng/mL for adults) to minimize neoplastic risk
Regular fasting glucose and HbA1c monitoring; consider berberine or metformin co-administration if insulin resistance develops
Thyroid panel (TSH, free T3, free T4) every 3–4 months; supplement T3 or T4 if subclinical hypothyroidism emerges
Use pulsatile injection timing (single daily dose before sleep or split 5-days-on/2-days-off protocol) to maintain pituitary sensitivity and reduce tachyphylaxis
Split dosing (e.g., morning + evening injections) at higher dose ranges to reduce peak IGF-1 spikes and moderate insulin antagonism
Annual MRI or relevant imaging in individuals with prior benign tumors or pituitary adenoma history

Qué hace

Over time, users typically notice improved sleep quality, reduced body fat (especially around the midsection), firmer skin, improved muscle tone and recovery between workouts, and increased energy levels. Bone density improvements take many months to show up.

Cómo funciona

Think of HGH as a construction company dispatcher — when the dispatcher (HGH) sends out more work orders, construction crews (IGF-1 and other signals) get busy building new muscle, repairing old tissue, and clearing out fat storage like demolishing old buildings to make room for new ones.

After injection, HGH is absorbed into the bloodstream and travels to receptors on cells throughout the body — especially in the liver, muscle, and fat tissue. The liver then produces IGF-1, which drives protein synthesis and cell growth. At the same time, HGH directly tells fat cells to break down and release stored energy.

Qué esperar

Initial effects like better sleep and improved energy may be noticed within 1–2 weeks. Visible changes in body composition typically begin after 4–6 weeks and become more pronounced after 3–6 months of consistent use.

Weeks 1–2: Better sleep quality, slightly more vivid dreams, mild increase in energy. Some users notice early water retention or hand tingling.
Weeks 2–6: Improved workout recovery, subtle reduction in body fat, noticeable improvement in skin texture and hydration. Water retention may peak then stabilize.
Weeks 6–24+: Significant lean muscle gains, meaningful fat loss (especially visceral fat), improved joint comfort, and enhanced overall body composition. Full effects require long-term consistent use.

Bueno saber

Start at a low dose (1–2 IU/day) and increase slowly to assess tolerance
Inject in the evening or before bed to mimic natural GH pulses and improve sleep quality
Monitor fasting blood glucose and IGF-1 levels every 6–8 weeks
Stay well hydrated to manage water retention side effects
Work with a physician who can order regular bloodwork and adjust dosing

Manteniéndose seguro

Water retention causing puffy hands, feet, or face — especially early on
Tingling or numbness in the hands (carpal tunnel-like symptoms)
Mild joint aches or stiffness
Elevated blood sugar levels — more noticeable if taken with meals

Evitar si tienes:

Anyone with a history of cancer or active tumors
People with uncontrolled diabetes
Pregnant or breastfeeding women
Anyone under 18 without a physician-diagnosed growth disorder

Descripción general

Sustained rhGH administration at supraphysiological doses produces: increased lean body mass (mean +3–5 kg over 6 months in GH-deficient adults in RCTs), decreased fat mass (mean −3–4 kg), improved VO2 max, enhanced collagen type I and III synthesis, increased bone mineral density (primarily after 12+ months), and IGF-1 normalization or elevation above normal range. Carbohydrate metabolism is impaired — fasting insulin levels rise and insulin sensitivity (measured by HOMA-IR) decreases by 20–35% in dose-dependent fashion.

Cómo funciona

GH receptor dimerization functions like two-key authentication on a safe — only when both receptor subunits are occupied and locked together does the JAK2 kinase 'turn on' and open the transcriptional programs downstream. IGF-1 then acts as a distributed secondary messenger — essentially a hormonal proxy that carries specific construction blueprints (anabolic signals) to muscle, bone, and connective tissue throughout the body.

Following subcutaneous injection, rhGH is absorbed with a bioavailability of approximately 75–80%, reaching peak serum concentrations (Cmax) within 2–4 hours. It is cleared primarily through hepatic and renal metabolism with a plasma half-life of 3–5 hours. IGF-1 levels rise with a delay of 8–24 hours post-injection and remain elevated for 12–18 hours, providing the sustained anabolic window. Chronic administration upregulates hepatic GHR density and increases basal IGF-1 substantially — clinical studies show IGF-1 increases of 30–60% from baseline at doses of 2–4 IU/day. GH also stimulates thyroid hormone metabolism, increasing T4-to-T3 conversion demands through deiodinase activity, potentially precipitating subclinical hypothyroidism.

Inicio y cronología

JAK2-STAT5 pathway activation occurs within minutes of receptor binding. Serum IGF-1 elevation is detectable within 8–12 hours post-injection. Measurable changes in nitrogen balance and lipolysis markers appear within 3–7 days of initiation. Detectable changes in lean body mass via DEXA scan typically emerge after 4–8 weeks at therapeutic doses (2–4 IU/day).

Days 1–7: JAK2-STAT5 signaling activates within hours of first injection. Serum IGF-1 rises measurably by day 2–3. Early fluid retention from renal sodium reabsorption may cause transient weight gain of 1–3 lbs. GH-mediated lipolysis begins, with elevated plasma free fatty acids detectable within 24–48 hours.
Weeks 1–4: Sustained IGF-1 elevation drives positive nitrogen balance and early anabolic remodeling. Sleep architecture improves (increased slow-wave/stage 3 sleep). Lipolytic effects become systemic — visceral adipocytes are particularly sensitive to GH-mediated HSL activation. Carpal tunnel symptoms may emerge in sensitive individuals as interstitial fluid accumulates.
Weeks 4–24+: Progressive lean mass accretion (predominantly myofibrillar protein synthesis augmented by IGF-1/IGF-1R signaling) becomes measurable by DEXA. Visceral and subcutaneous fat decreases measurably. Collagen synthesis improvements manifest as improved skin elasticity and tendon/ligament resilience. Bone turnover markers (osteocalcin, P1NP) rise, reflecting increased osteoblast activity. At 6 months, full metabolic reprogramming toward anabolic/lipolytic phenotype is established.

Cómo aprovecharlo al máximo

Monitor serum IGF-1 every 6–8 weeks; keep IGF-1 within age-adjusted normal range (typically 150–300 ng/mL for adults) to minimize neoplastic risk
Regular fasting glucose and HbA1c monitoring; consider berberine or metformin co-administration if insulin resistance develops
Thyroid panel (TSH, free T3, free T4) every 3–4 months; supplement T3 or T4 if subclinical hypothyroidism emerges
Use pulsatile injection timing (single daily dose before sleep or split 5-days-on/2-days-off protocol) to maintain pituitary sensitivity and reduce tachyphylaxis
Split dosing (e.g., morning + evening injections) at higher dose ranges to reduce peak IGF-1 spikes and moderate insulin antagonism
Annual MRI or relevant imaging in individuals with prior benign tumors or pituitary adenoma history

Efectos secundarios comunes

Peripheral edema due to sodium and water retention from GH-mediated renal tubular sodium reabsorption — affects 10–20% of users at clinical doses
Carpal tunnel syndrome from fluid accumulation compressing the median nerve — incidence approximately 10–15% at doses >2 IU/day
Insulin resistance and hyperinsulinemia — clinically significant at doses >3–4 IU/day, particularly in those with pre-existing metabolic syndrome
Arthralgias and myalgias — transient in most users, resolving with dose reduction

Mecanismo de acción

Recombinant human growth hormone (rhGH) binds as a bivalent ligand to two GH receptor (GHR) molecules, inducing receptor homodimerization and transactivation of the associated Janus kinase 2 (JAK2). JAK2 phosphorylates the intracellular domain of GHR and recruits STAT5b (signal transducer and activator of transcription 5b), which dimerizes and translocates to the nucleus to drive transcription of IGF-1, IGF-binding proteins, and other anabolic gene targets. In parallel, GH activates the MAPK/ERK and PI3K/AKT signaling cascades in peripheral tissues — promoting lipolysis in adipocytes through phosphorylation of hormone-sensitive lipase and perilipin, and inducing a counter-regulatory anti-insulin effect via IRS-1 serine phosphorylation that reduces GLUT4 translocation.

Following subcutaneous injection, rhGH is absorbed with a bioavailability of approximately 75–80%, reaching peak serum concentrations (Cmax) within 2–4 hours. It is cleared primarily through hepatic and renal metabolism with a plasma half-life of 3–5 hours. IGF-1 levels rise with a delay of 8–24 hours post-injection and remain elevated for 12–18 hours, providing the sustained anabolic window. Chronic administration upregulates hepatic GHR density and increases basal IGF-1 substantially — clinical studies show IGF-1 increases of 30–60% from baseline at doses of 2–4 IU/day. GH also stimulates thyroid hormone metabolism, increasing T4-to-T3 conversion demands through deiodinase activity, potentially precipitating subclinical hypothyroidism.

Farmacodinamia

JAK2-STAT5 pathway activation occurs within minutes of receptor binding. Serum IGF-1 elevation is detectable within 8–12 hours post-injection. Measurable changes in nitrogen balance and lipolysis markers appear within 3–7 days of initiation. Detectable changes in lean body mass via DEXA scan typically emerge after 4–8 weeks at therapeutic doses (2–4 IU/day).

Sustained rhGH administration at supraphysiological doses produces: increased lean body mass (mean +3–5 kg over 6 months in GH-deficient adults in RCTs), decreased fat mass (mean −3–4 kg), improved VO2 max, enhanced collagen type I and III synthesis, increased bone mineral density (primarily after 12+ months), and IGF-1 normalization or elevation above normal range. Carbohydrate metabolism is impaired — fasting insulin levels rise and insulin sensitivity (measured by HOMA-IR) decreases by 20–35% in dose-dependent fashion.

Cronología

Days 1–7: JAK2-STAT5 signaling activates within hours of first injection. Serum IGF-1 rises measurably by day 2–3. Early fluid retention from renal sodium reabsorption may cause transient weight gain of 1–3 lbs. GH-mediated lipolysis begins, with elevated plasma free fatty acids detectable within 24–48 hours.
Weeks 1–4: Sustained IGF-1 elevation drives positive nitrogen balance and early anabolic remodeling. Sleep architecture improves (increased slow-wave/stage 3 sleep). Lipolytic effects become systemic — visceral adipocytes are particularly sensitive to GH-mediated HSL activation. Carpal tunnel symptoms may emerge in sensitive individuals as interstitial fluid accumulates.
Weeks 4–24+: Progressive lean mass accretion (predominantly myofibrillar protein synthesis augmented by IGF-1/IGF-1R signaling) becomes measurable by DEXA. Visceral and subcutaneous fat decreases measurably. Collagen synthesis improvements manifest as improved skin elasticity and tendon/ligament resilience. Bone turnover markers (osteocalcin, P1NP) rise, reflecting increased osteoblast activity. At 6 months, full metabolic reprogramming toward anabolic/lipolytic phenotype is established.

Comparaciones

HGH (rhGH) — efectividad Very High, seguridad Moderate, costo $$$$, High de usar
Ipamorelin + CJC-1295 — efectividad High, seguridad Good, costo $$, Medium de usar
IGF-1 LR3 — efectividad High, seguridad Caution, costo $$$, High de usar
Sermorelin — efectividad Moderate, seguridad Good, costo $$, Medium de usar

Efectos adversos

Comunes:

Peripheral edema due to sodium and water retention from GH-mediated renal tubular sodium reabsorption — affects 10–20% of users at clinical doses
Carpal tunnel syndrome from fluid accumulation compressing the median nerve — incidence approximately 10–15% at doses >2 IU/day
Insulin resistance and hyperinsulinemia — clinically significant at doses >3–4 IU/day, particularly in those with pre-existing metabolic syndrome
Arthralgias and myalgias — transient in most users, resolving with dose reduction

Raros:

Intracranial hypertension (pseudotumor cerebri) — rare, primarily in pediatric populations (<1%)
Pancreatitis — rare case reports, mechanism unclear but possibly related to lipid metabolism changes
New-onset type 2 diabetes mellitus with prolonged supraphysiological use — estimated incidence 1–2% in long-term studies
Progression of pre-existing neoplasms — theoretical risk supported by IGF-1's mitogenic role; no definitive causal RCT data in adults

Contraindicaciones y mitigación de riesgos

Contraindicado en:

Patients with active or suspected malignancy — GH/IGF-1 axis promotes cell proliferation via PI3K/AKT and MAPK pathways
Individuals with diabetic retinopathy — retinal neovascularization may be exacerbated by IGF-1-mediated VEGF upregulation
Patients with severe obesity (BMI >40) — increased risk of adverse metabolic effects including worsened insulin resistance
Individuals with untreated hypothyroidism — GH increases peripheral T4-to-T3 conversion, potentially unmasking subclinical deficiency
Those with active Prader-Willi syndrome and compromised respiratory function — increased risk of sleep apnea and sudden death

Monitor serum IGF-1 every 6–8 weeks; keep IGF-1 within age-adjusted normal range (typically 150–300 ng/mL for adults) to minimize neoplastic risk
Regular fasting glucose and HbA1c monitoring; consider berberine or metformin co-administration if insulin resistance develops
Thyroid panel (TSH, free T3, free T4) every 3–4 months; supplement T3 or T4 if subclinical hypothyroidism emerges
Use pulsatile injection timing (single daily dose before sleep or split 5-days-on/2-days-off protocol) to maintain pituitary sensitivity and reduce tachyphylaxis
Split dosing (e.g., morning + evening injections) at higher dose ranges to reduce peak IGF-1 spikes and moderate insulin antagonism
Annual MRI or relevant imaging in individuals with prior benign tumors or pituitary adenoma history

Reference data

Specifications

Molecular formula: C990H1528N262O300S7
Molecular weight: 22,124 Da (22.1 kDa)
Half-life: ~15–20 minutes (endogenous GH pulse); ~3–5 hours (exogenous rhGH subcutaneous)
Route: Subcutaneous, Intramuscular
Cycle length: 12–24 weeks minimum for notable body composition changes; clinical protocols are indefinite
Storage: Lyophilized (unreconstituted): store at 2–8°C (refrigerated); may tolerate room temperature briefly. Reconstituted with bacteriostatic water: store at 2–8°C and use within 28–30 days. Never freeze reconstituted HGH. Protect from light and heat. Use sterile bacteriostatic water for reconstitution to extend shelf life.
Legal status: Prescription-only in the US (FDA-approved for specific indications including GH deficiency, Prader-Willi syndrome, Turner syndrome, HIV-associated wasting, and short bowel syndrome). Off-label use for anti-aging and bodybuilding is illegal without prescription. Schedule III controlled in some jurisdictions; banned by WADA in competitive sports.

FAQ

Common questions

Does exogenous rhGH cause permanent pituitary suppression?

Exogenous GH suppresses endogenous pulsatile GH secretion through negative feedback on hypothalamic GHRH release and somatostatin tone upregulation. However, this suppression is generally reversible upon cessation. Long-term somatotroph desensitization has been documented in some studies but recovery to baseline GH secretory capacity typically occurs within weeks to months post-discontinuation. Unlike gonadal axis suppression from exogenous androgens, pituitary recovery from GH suppression is more rapid.

What is the evidence basis for cancer risk with long-term rhGH use?

The IGF-1 axis has well-established mitogenic and anti-apoptotic roles mediated through IGF-1R/PI3K/AKT/mTOR signaling. Epidemiological data show associations between high-normal or elevated serum IGF-1 and increased risk of colorectal, breast, and prostate cancers. However, causality in the context of therapeutic rhGH use has not been definitively established in prospective RCTs. Long-term surveillance studies of GH-deficient adults on replacement therapy (e.g., KIMS database, HypoCCS registry) have not shown a statistically significant increase in de novo cancer incidence at replacement doses, though supraphysiological bodybuilding doses are not represented in these datasets. The precautionary principle strongly supports maintaining IGF-1 within normal reference ranges.

How does rhGH compare pharmacologically to GH secretagogues like Ipamorelin/CJC-1295?

Exogenous rhGH bypasses endogenous regulatory mechanisms entirely, delivering a consistent pharmacological dose independent of pituitary feedback. GH secretagogues (GHRP/GHRH analogs like Ipamorelin/CJC-1295) stimulate endogenous pituitary GH release in a pulsatile, feedback-regulated manner, maintaining physiological GH secretory patterns and preserving somatostatin counterregulation. This makes secretagogues lower-risk from a pituitary suppression and IGF-1 overshoot standpoint, though their peak GH elevation is lower than directly administered rhGH. For clinical GH deficiency, rhGH remains the gold standard; for wellness/anti-aging, secretagogue stacks may offer a more physiological and lower-risk profile.

What is the evidence level?

This compound is classified as Clinical evidence. Randomized controlled trial data in humans exists and supports use in specific contexts.

Research

Research & sources

Clinical evidence

Current evidence for Human Growth Hormone (HGH) is rated as Clinical evidence. Human clinical evidence supports the reported effects.

1. Growth hormone and the insulin-like growth factor system in myogenesis (2010) — Endocrine Reviews (doi:10.1210/er.2009-0024)
2. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II (2007 revision) (2007) — European Journal of Endocrinology (doi:10.1530/EJE-07-0631)
3. Effects of growth hormone on glucose metabolism and insulin resistance in human (2019) — Annals of Pediatric Endocrinology & Metabolism (doi:10.6065/apem.2019.24.2.92)
4. Cancer risk following growth hormone use in childhood: implications for current practice (2012) — Drug Safety (doi:10.2165/11632080-000000000-00000)
5. GH replacement in hypopituitary adults: long-term effects on body composition — evidence from the KIMS database (2013) — European Journal of Endocrinology (doi:10.1530/EJE-13-0286)

Explore

Often discussed alongside

IGF-1 LR3 · growth BPC-157 · healing TB-500 · healing Ipamorelin · growth CJC-1295 · growth GHRP-6 · growth